A detailed history of Granite Shares Advisors LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Granite Shares Advisors LLC holds 2,683 shares of VRTX stock, worth $1.39 Million. This represents 0.86% of its overall portfolio holdings.

Number of Shares
2,683
Previous 2,818 4.79%
Holding current value
$1.39 Million
Previous $1.32 Million 5.53%
% of portfolio
0.86%
Previous 0.44%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 28, 2024

SELL
$460.0 - $505.78 $62,100 - $68,280
-135 Reduced 4.79%
2,683 $1.25 Million
Q2 2024

Aug 01, 2024

BUY
$392.81 - $485.53 $35,352 - $43,697
90 Added 3.3%
2,818 $1.32 Million
Q1 2024

Apr 22, 2024

BUY
$407.69 - $446.08 $6,523 - $7,137
16 Added 0.59%
2,728 $1.14 Million
Q4 2023

Jan 30, 2024

SELL
$343.0 - $410.68 $152,978 - $183,163
-446 Reduced 14.12%
2,712 $1.1 Million
Q3 2023

Oct 31, 2023

BUY
$338.18 - $362.46 $813,661 - $872,078
2,406 Added 319.95%
3,158 $1.1 Million
Q2 2023

Aug 10, 2023

SELL
$314.42 - $351.91 $3,773 - $4,222
-12 Reduced 1.57%
752 $264,000
Q1 2023

Apr 24, 2023

SELL
$283.23 - $323.1 $3,398 - $3,877
-12 Reduced 1.55%
764 $240,000
Q4 2022

Jan 26, 2023

SELL
$285.76 - $321.48 $43,149 - $48,543
-151 Reduced 16.29%
776 $0
Q3 2022

Oct 14, 2022

SELL
$273.83 - $305.53 $29,025 - $32,386
-106 Reduced 10.26%
927 $268,000
Q2 2022

Jul 22, 2022

SELL
$234.96 - $292.55 $23,965 - $29,840
-102 Reduced 8.99%
1,033 $291,000
Q1 2022

May 06, 2022

SELL
$221.42 - $260.97 $22,142 - $26,097
-100 Reduced 8.1%
1,135 $296,000
Q4 2021

Feb 08, 2022

BUY
$177.01 - $223.45 $218,607 - $275,960
1,235 New
1,235 $271,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $133B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Granite Shares Advisors LLC Portfolio

Follow Granite Shares Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Granite Shares Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Granite Shares Advisors LLC with notifications on news.